Summary of Significant Accounting Policies (Tables)

9 Months Ended

Mar. 31, 2023

Summary of Significant Accounting Policies

Reconciliation of the cash, cash equivalents and restricted cash

	March 31, 2023		March 31, 2022
Cash and cash equivalents	$	46,540	$	106,108
Restricted cash, included in other assets		5,000		5,000
Cash, cash equivalents and restricted cash as presented on the Consolidated Statements of Cash Flows	$	51,540	$	111,108

Schedule of the Company's net sales by medical indication

	Three Months Ended				Nine Months Ended
(In thousands)	March 31,				March 31,
Medical Indication	2023		2022		2023		2022
Analgesic	$	2,741	$	3,292	$	8,757	$	12,525
Anti-Psychosis		2,082		3,346		7,277		9,156
Cardiovascular		13,059		9,468		37,030		33,321
Central Nervous System		19,311		15,177		61,887		60,302
Endocrinology		8,066		6,792		21,209		22,934
Gastrointestinal		9,932		11,709		26,590		40,972
Infectious Disease		2,826		5,438		12,884		24,473
Migraine		2,768		3,507		9,666		12,638
Respiratory/Allergy/Cough/Cold		981		2,309		3,651		7,291
Other		13,342		14,700		33,056		35,327
Contract manufacturing revenue		5,399		2,619		14,473		7,451
Total net sales	$	80,507	$	78,357	$	236,480	$	266,390

Summary of customers which accounted for at least 10% of total net sales

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2023		2022		2023		2022
Customer A	26	%	17	%	23	%	25	%
Customer B	17	%	19	%	19	%	18	%
Customer C	14	%	12	%	15	%	14	%